Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.66
- Piotroski Score 2.00
- Grade Buy
- Symbol (ABUS)
- Company Arbutus Biopharma Corporation
- Price $3.82
- Changes Percentage (-3.54%)
- Change -$0.14
- Day Low $3.79
- Day High $3.96
- Year High $4.72
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.50
- High Stock Price Target $8.50
- Low Stock Price Target $8.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.44
- Trailing P/E Ratio -7.27
- Forward P/E Ratio -7.27
- P/E Growth -7.27
- Net Income $-72,849,000
Income Statement
Quarterly
Annual
Latest News of ABUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'It is abusive': Iowa AG rips leading pediatric group for not 'following the science' for trans youth
Iowa Attorney General Brenna Bird urges the American Academy of Pediatrics to update guidelines for transgender youth, citing risks of puberty blockers. She joined AGs in criticizing the AAP's support...
By Fox News | 1 day ago -
Pope blasted by Belgian PM and King for church's sex abuse cover-up
Belgium's Prime Minister criticizes Pope Francis over Catholic Church's sex abuse cover-up, demanding accountability and prioritizing survivors. The Pope's visit for a university celebration is marred...
By Newsweek | 1 day ago -
Wild goose disgrace: NJ man slapped with animal abuse after fatally...
A man in Hoboken, N.J., was charged with animal cruelty for intentionally running over a goose with an e-bike, killing it. The suspect fled but was later identified. He faces up to six months in jail ...
By New York Post | 1 day ago
